Department of Thoracic Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Department of Thoracic Surgery, First People's Hospital of Yunnan Province, Kunming, Yunnan, China.
Neoplasma. 2022 Mar;69(2):311-320. doi: 10.4149/neo_2021_210804N1107. Epub 2021 Dec 29.
RHBDD1 overexpression is found in various malignancies, including non-small cell lung cancer (NSCLC), and it is correlated with NSCLC patients' poor overall survival. This study aims to explore the function of RHBDD1 in regulating the progression of NSCLC and its potential molecular basis. qPCR, immunohistochemistry, and/or western blotting were used to evaluate the expression of RHBDD1 in NSCLC tissues and cell lines. RHBDD1 knockdown and overexpression were performed, CCK-8 assay and cell clone formation were applied to study the function of RHBDD1 in cell proliferation in vitro. Flow cytometry and immunofluorescence tests were employed to determine the regulation of apoptosis, cell cycle, and endoplasmic reticulum stress by RHBDD1. As a result, RHBDD1 was found significantly upregulated in NSCLC tissues and cells and associated with pathological tumor staging. RHBDD1 knockdown inhibited the proliferation of NSCLC cells both in vitro and in vivo, promoted their apoptosis, caused cell cycle arrest at G0/G1 phase, characterized with reduced CDK2, suppressed TGF-α secretion, and inhibited the EGFR/Raf/MEK/ERK signaling pathway. In contrast, RHBDD1 overexpression showed the opposite effects. These effects of the manipulated expression of RHBDD1 on NSCLC were restored by EGFR or MEK inhibitor. Additionally, RHBDD1 knockdown and overexpression resulted in decreased and increased BIK cleavage, respectively, but the effects could be blocked by a proteasome inhibitor. In conclusion, our research shows that RHBDD1 promotes the progression of NSCLC through enhancement of proliferation and induction of apoptosis by regulating the EGFR/Raf/MEK/ERK signaling pathway and the level of BIK protein level.
RHBDD1 的过表达存在于各种恶性肿瘤中,包括非小细胞肺癌(NSCLC),并且与 NSCLC 患者的总体生存不良相关。本研究旨在探讨 RHBDD1 在调节 NSCLC 进展中的作用及其潜在的分子基础。qPCR、免疫组织化学和/或 Western blot 用于评估 RHBDD1 在 NSCLC 组织和细胞系中的表达。进行 RHBDD1 敲低和过表达,应用 CCK-8 assay 和细胞克隆形成来研究 RHBDD1 在体外细胞增殖中的功能。流式细胞术和免疫荧光试验用于确定 RHBDD1 对细胞凋亡、细胞周期和内质网应激的调节作用。结果发现,RHBDD1 在 NSCLC 组织和细胞中显著上调,并且与病理肿瘤分期相关。RHBDD1 敲低抑制 NSCLC 细胞在体外和体内的增殖,促进其凋亡,导致细胞周期停滞在 G0/G1 期,表现为 CDK2 减少,TGF-α 分泌受抑制,并且抑制 EGFR/Raf/MEK/ERK 信号通路。相反,RHBDD1 过表达则表现出相反的效果。对 RHBDD1 表达的操纵对 NSCLC 的这些影响可以通过 EGFR 或 MEK 抑制剂恢复。此外,RHBDD1 敲低和过表达分别导致 BIK 切割减少和增加,但这些作用可以被蛋白酶体抑制剂阻断。总之,我们的研究表明,RHBDD1 通过调节 EGFR/Raf/MEK/ERK 信号通路和 BIK 蛋白水平,促进 NSCLC 的进展,增强增殖并诱导细胞凋亡。